Long-acting cabotegravir and rilpivirine in pregnancy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 4, open-label, multi-site study looks at the pharmacokinetics of long-acting cabotegravir and rilpivirine in pregnant individuals with HIV who are already virally suppressed. Up to 40 adults will enroll with their infants to obtain 30 evaluable adults, including those who started CAB LA + RPV LA before or during pregnancy. Participants receive the injections every 4 weeks and are followed through pregnancy and postpartum to assess drug levels and safety. The trial requires adherence to prenatal care and delivery at participating sites. Data will inform dosing and safety of this regimen during pregnancy and after delivery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Willing and able to provide written informed consent for study participation for self and infant
* At screening, age 18 years or older
* Has a viable, intrauterine, singleton pregnancy with fetal ultrasound with an estimated gestational age (EGA) between 10 0/7 and 23 6/7 weeks (inclusive) at entry
* At entry, intending to deliver at a study-associated medical facility and remain in the geographic area of the study for the duration of anticipated follow-up
* Was diagnosed with HIV prior to the current pregnancy
* Has a documented plasma HIV RNA result less than 50 copies/mL from a specimen collected within 28 days prior to entry
* Has the following laboratory test results from a specimen collected within 28 days prior to entry (1) Grade 2 or lower platelets (greater than or equal to 50,000 cells/mm3 or greater than or equal to 50.00 x 109 cells/L); (2) Grade 1 or lower ALT (less than 2.5 x upper limit of normal; (3) Grade 1 or lower aspartate aminotransferase (AST)
* Received first dose of CAB LA + RPV LA prior to entry (before or after conception of the current pregnancy) and is expected to receive CAB LA + RPV LA on a Q4W schedule for the duration of study participation

Exclusion Criteria:

* History of treatment/virologic failure associated with documented or suspected viral resistance to CAB or RPV (including oral RPV)
* Has any of the following (1) HIV Subtype A6; (2) History of hypersensitivity reaction (HSR), known or suspected allergy to drugs under study, or any other contraindication to CAB or RPV; (3) Current contraindication to IM injection such as a current inflammatory skin condition that compromises the safety of IM injections or a dermatological condition which may interfere with the interpretation of ISRs; (4) Current use or anticipated need of therapeutic anticoagulation; (5) History of known or suspected bleeding disorder; (6) Current severe hepatic impairment (Class C) as determined by Child-Pugh classification; (7) History of suicidal ideation or attempt within six months of entry; (8) History of unstable or poorly controlled seizure disorder; (9) Current tuberculosis infection; (10) Current cervical intraepithelial neoplasia (CIN) 2 or 3, or malignancy other than Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma
* Has any of the following during the current pregnancy: (1) Abnormal placentation, including placenta previa (complete) and placenta accreta/increta/percreta; (2) Cervical cerclage/cervical incompetence; (3) Abnormal fetal anatomy
* Had any of the following in a previous pregnancy: (1) Eclampsia/Hemolysis, Elevated Liver enzymes and Low Platelets (HELLP) syndrome; (2) Intrauterine fetal demise (EGA greater than 20 weeks) without known nonrecurrent etiology; (3) Spontaneous very preterm delivery (less than 32 weeks); (4) Very LBW (less than 1500 g); (5) Cervical or abdominal cerclage due to cervical incompetence
* Receipt of any prohibited medication within seven days prior to entry
* Enrolled in another clinical trial of an investigational agent, device, or vaccine that may impact the PK of CAB or RPV
* Receipt of an investigational agent or chemotherapy within 30 days prior to study entry
* Adult-participant or fetus has any condition, such as uncontrolled diabetes, hypertension, or other comorbidities, that, in the opinion of the site investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives

Where it's running

• Site 5052, University of Colorado
  Aurora, Colorado, United States Recruiting
• Site 4001, Lurie Children's Hospital of Chicago CRS
  Chicago, Illinois, United States Recruiting
• Site 6201, University of Pennsylvania
  Philadelphia, Pennsylvania, United States Recruiting
• Site 5128, Baylor College of Medicine/Texas Children's Hospital
  Houston, Texas, United States Recruiting
• Site 4601, University of California, UC San Diego CRS
  La Jolla, California, United States Not yet recruiting
• Site 5048, University of Southern California
  Los Angeles, California, United States Not yet recruiting

Study contacts

• Study coordinator: Lisa Levy
• Email: LLEVY@FHI360.ORG
• Phone: 2028848480

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Restarting HIV treatment with a single-pill regimen (B/F/TAF) after a treatment gap

  This study tests whether quickly restarting ART with the single-pill regimen B/F/TAF is safe and effective for people with HIV who have had a treatment interruption of at least 12 weeks.

  Recruiting at 10 sites Phase 4 CAN Community Health · Clearwater, Florida and 9 other locations · NCT07476339

• Weekly long-acting HIV-1 meds switch for people with undetectable virus

  This study tests whether switching to weekly oral long-acting HIV medicines works as well as staying on current daily pills for people with HIV who already have an undetectable viral load.

  Recruiting at 2 sites Phase 2 Gilead Sciences · Ft. Pierce, Florida and 1 other locations · NCT07841990

• HIV in Hong Kong: patterns, transmission, and burden over time

  This project tests how HIV-1 infections in Hong Kong have changed over several years by following newly diagnosed adults and analyzing their subtypes, transmission links, and community burden.

  Recruiting Chinese University of Hong Kong · North Point · NCT07725042

• GS-0415 safety and PK in people with HIV on ART

  This study tests GS-0415 in adults with HIV who are on stable ART to see if it is safe, tolerable, and how the drug behaves in the body.

  Recruiting at 15 sites Phase 1 Gilead Sciences · Los Angeles, California and 15 other locations · NCT07719491

• Gilead study of GS-3242 with Lenacapavir for people starting HIV treatment compared with Biktarvy

  This study tests whether injecting GS-3242 with Lenacapavir can work as well as Biktarvy for people newly starting HIV treatment.

  Recruiting at 19 sites Phase 2/3 Gilead Sciences · Torrance, California and 20 other locations · NCT07708727

• RNA-based vaccine BNT168 safety and immune response in adults with or without HIV

  A first-in-human study tests whether the RNA vaccine BNT168 is safe and can trigger immune responses in adults both with and without HIV.

  Recruiting at 3 sites Phase 1 BioNTech SE · Houston, Texas and 3 other locations · NCT07698600

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.